Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
Loading PTN News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.46%73.760.9%$699.22m
AMGNAmgen Inc.
0.50%180.211.1%$562.99m
CELGCelgene Corporation
1.05%137.741.1%$511.41m
REGNRegeneron Pharmaceuticals, Inc.
-1.00%515.922.7%$478.88m
VRTXVertex Pharmaceuticals Incorporated
2.41%163.171.9%$401.70m
BIIBBiogen Inc.
0.53%282.921.2%$362.26m
ALXNAlexion Pharmaceuticals, Inc.
1.53%131.791.9%$271.34m
TSROTESARO, Inc.
2.29%131.9714.7%$172.59m
ILMNIllumina, Inc.
0.45%172.753.5%$161.08m
INCYIncyte Corporation
0.32%134.222.6%$151.82m
EXELExelixis, Inc.
0.89%27.236.5%$148.60m
CLVSClovis Oncology, Inc.
1.61%86.6418.0%$130.90m
BMRNBioMarin Pharmaceutical Inc.
1.76%89.284.4%$127.08m
KITEKite Pharma, Inc.
-0.67%109.1516.1%$120.98m
SRPTSarepta Therapeutics, Inc.
6.06%43.4119.8%$112.50m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product in development is bremelanotide for the treatment of female sexual dysfunction. It is also developing an inhalation formulation of peptide mimetic natriuretic peptide receptor A-agonist, for treatment of cardiovascular and pulmonary indications. The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.